Drugs & Therapy Perspectives

, Volume 10, Issue 12, pp 7–9 | Cite as

Nelfinavir: a new protease inhibitor for HIV infection

New Drugs and Disease Management
  • 13 Downloads

Keywords

Lamivudine Zidovudine Triple Therapy Didanosine Nelfinavir 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Perry CM, Benfield P. Nelfinavir. Drugs 1997 Jul; 54(1): 81–7PubMedCrossRefGoogle Scholar
  2. 2.
    Gathe Jr JC. Nelfinavir: a viewpoint. Drugs 1997 Jul; 54(1): 88CrossRefGoogle Scholar
  3. 3.
    Breckenridge A. Nelfinavir: a viewpoint. Drugs 1997 Jul; 54(1): 88CrossRefGoogle Scholar
  4. 4.
    Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor AG1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother 1995 Sep 17–20 Program Addendum: 8Google Scholar
  5. 5.
    Conant M, Markowitz M, Hurley A, et al. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept® as monotherapy in HIV positive patients [abstract]. 11th International Conference on AIDS. 1996 Jul 7–12; Vancouver, 286–7Google Scholar
  6. 6.
    Moyle G, Youle M, Chapman S, et al. A phase II dose escalation study of the Agouron protease inhibitor AG 1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother. 1995 Sep 17–20 Program Addendum: 8Google Scholar
  7. 7.
    Gathe JJ, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept®, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone [abstract]. 11th International Conference on AIDS. 1996 Jul 7–12; Vancouver, 25Google Scholar
  8. 8.
    Clinical trials update. Scrip 1996 Jun 18(2138): 20Google Scholar
  9. 9.
    Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society — USA Panel. JAMA 1997 Jun 25;277: 1962–9CrossRefGoogle Scholar
  10. 10.
    Markowitz M, Winslow D, Cao Y, et al. Triple therapy with nelfinavir (Viracept® in combination with AZT and 3TC in 12 antiviral-naive subjects chronically infected with HIV-1 [abstract]. Tenth International Conference on Antiviral Research. 1997 Apr 6–11; AtlantaGoogle Scholar
  11. 11.
    Henry K, Lamarca A, Myers R, et al. The safety of VIRACEPT® (nelfinavir mesylate) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC [Poster]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DCGoogle Scholar
  12. 12.
    Connett S. First dual protease inhibitor combination shows promise. Bioworld Today 1996 Jul 11; 7:1,3Google Scholar
  13. 13.
    Prescott L. Redefining the approach to treating HIV infection. Inpharma 1996 Aug 30; 1052: 13–4Google Scholar
  14. 14.
    Pedneault L, Elion R, Adler M, et al. Stavudine (d4T), didanosine (ddl), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DCGoogle Scholar
  15. 15.
    Agouron Pharmaceuticals Inc. Nelfinavir mesylate Prescribing Information. La Jolla, California, USA, 1993Google Scholar
  16. 16.
    Deeks SG, Smith M, Holodniy M, et al. HIV-1 Protease Inhibitors. A Review for Clinicians. JAMA 1997; 277(2) 145–153PubMedCrossRefGoogle Scholar
  17. 17.
    Agouron Pharmaceuticals Inc. Agouron reports positive results from pivotal clinical trials of Viracept®. Media Release: 1997 Jan 23Google Scholar

Copyright information

© Adis International Limited 1997

Personalised recommendations